272 Capital LP 13D and 13G filings for Harvard Bioscience, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 12:31 pm Sale | 2024-09-30 | 13G | Harvard Bioscience, Inc. HBIO | 272 Capital LP | 1,555,820 3.600% | -1,383,458 (-47.07%) | Filing |
| 2024-02-14 08:46 am Sale | 2023-12-31 | 13G | Harvard Bioscience, Inc. HBIO | 272 Capital LP | 2,939,278 6.900% | -325,518 (-9.97%) | Filing |
| 2023-02-16 3:11 pm Unchanged | 2022-12-31 | 13G | Harvard Bioscience, Inc. HBIO | 272 Capital LP | 3,264,796 7.800% | 0 (Unchanged) | Filing |
| 2023-02-15 5:30 pm Purchase | 2022-11-29 | 13G | Harvard Bioscience, Inc. HBIO | 272 Capital LP | 3,264,796 7.840% | 3,264,796 (New Position) | Filing |